RecruitingNot ApplicableNCT05917795

Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates

Prospective Pilot Study for the Evaluation of Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates


Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Enrollment

24 participants

Start Date

Sep 24, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The aim of this pilot prospective interventional study is to evaluate the efficacy of endoscopic sleeve gastroplasty (ESG) in allowing obese subjects (≥35 kg/m2) with end stage renal disease who need of kidney transplantation to reduce their BMI below 35 in order to be inserted in the waiting list BMI. The main question\[s\] it aims to answer are: Is the procedure effective in reducing BMI to the target level in 12 months? Which is the effect on weight loss, quality of life and obesity-related comorbidities? Participants will undergo ESG as per standard clinical practice and followed up to 12 months before transplantation and for 12 months after transplantation.


Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study is testing an endoscopic sleeve gastroplasty (ESG) — a minimally invasive, non-surgical stomach-folding procedure done through a tube down the throat — to help obese patients with severe kidney disease lose weight before a kidney transplant. **You may be eligible if...** - You are 18–70 years old - Your BMI is 35 or higher - You have advanced chronic kidney disease (stage G4–G5) and are a candidate for kidney transplantation - You are either pre-dialysis (pre-emptive transplant candidate) or already on dialysis **You may NOT be eligible if...** - Your BMI is below 35 - You have had prior bariatric (weight loss) surgery - You have severe heart disease or other conditions making endoscopy unsafe - You are pregnant - You are not a kidney transplant candidate Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREEndoscopic Sleeve Gastroplasty (ESG)

ESG will be performed under general anaesthesia with orotracheal intubation. The Endomina® suturing system (EndoTools Therapeutics S.A., Gosselies, Belgium) mounted on a single channel endoscope (GIF-H190/GIF-HQ190; Olympus Medical Systems Corp., Tokyo, Japan) will be used. This system allows to obtain full thickness gastric sutures through the gastric wall of the gastric body, leaving the antrum and the gastric fundus free. The ESG starts with the reduction of the gastric body, suturing from distal to proximal and starting from the notch of the angulus and ending at the level of the fundus. 4-8 full thickness stitches will be placed, with 2 passes per stitch. The final effect of ESG is the creation of a gastric tubule thus reducing the volume of the stomach. After the procedure, the final shape will be evaluated, to examine any gaps that would require additional closure, and to exclude bleedings and/or other complications.


Locations(1)

Fondazione Policlinico Universitario A. Gemelli IRCCS

Rome, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05917795


Related Trials